| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Edgewise Therapeutics, Inc. (EWTX) has 15 insiders with recent SEC Form 4 filings, including 2 buys and 28 sells. EWTX is classified in the Biotechnology industry within the Health Care sector.
| Role | Insider | Shares | Value | 30d |
|---|---|---|---|---|
| CFO | 262.5K | $9.27M | - | |
| Other | 105.0K | $3.71M | - | |
| Dir | 45.1K | $1.59M | - | |
| CEO | 38.6K | $1.36M | - | |
| Dir | 30.0K | $1.06M | - |
Buys and sells only
| Date | Insider | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Jun 21, 2022 | Moore John R45 | General Counsel | Sale+OE | 67,927 | $6.83 | $463,934.93 | -88.3% | +20.5% | +7.7% | |
| Jun 15, 2022 | Moore John R45 | General Counsel | Sale+OE | 26,381 | $6.08 | $160,456.51 | -46.7% | +67.0% | +41.1% | |
| Jun 10, 2022 | Moore John R45 | General Counsel | Sale+OE | 27,306 | $6.44 | $175,878.36 | -75.2% | +102.3% | +61.6% | |
| Jun 7, 2022 | Moore John R45 | General Counsel | Sale+OE | 47,287 | $6.26 | $295,984.99 | -79.8% | +56.8% | +47.8% | |
| May 18, 2022 | Orbimed Advisors LLC67 | Director, 10% Owner | Buy | 138,000 | $7.21 | $994,980.00 | +1.0% | +51.1% | +28.2% | |
| May 18, 2022 | Thompson Peter A.65 | Director, 10% Owner | Buy | 138,000 | $7.21 | $994,980.00 | +1.0% | +51.1% | +28.2% | |
| May 16, 2022 | Moore John R45 | General Counsel | Sell | 10,800 | $7.42 | $80,145.72 | -78.3% | +47.6% | +28.4% | |
| Nov 15, 2021 | Russell Alan J77 | Chief Scientific Officer | Sell | 479 | $19.11 | $9,155.40 | -92.6% | -41.5% | -46.5% | |
| Nov 12, 2021 | Russell Alan J77 | Chief Scientific Officer | Sell | 69,740 | $19.91 | $1,388,787.60 | -28.7% | -34.5% | -44.2% | |
| Nov 8, 2021 | Russell Alan J77 | Chief Scientific Officer | Sell | 29,451 | $19.82 | $583,823.46 | -8.1% | -37.7% | -52.2% |